Ondansetron, 2 mg/ml 2 ml 5 pcs

Ondansetron is an antiemetic.

Ondansetron effectively prevents and eliminates nausea and vomiting occurring against the background of anti-tumor chemotherapy or radiation therapy, as well as in the postoperative period. The mechanism of action is due to the ability of ondansetron to selectively block the serotonin 5-HT3 receptors.

It is believed that stimulation of afferent fibers of vagus nerve by serotonin released from enterochromaffin cells of gastrointestinal mucosa plays an important role in the occurrence of nausea and vomiting during antitumor therapy. By blocking 5-HT3-receptors, ondansetron prevents the occurrence of the gag reflex.

In addition ondansetron inhibits central links of the gag reflex by blocking 5-HT3-receptors of the floor of the IV ventricle (area postrema).

Indications

Prevention of nausea and vomiting during antitumor chemotherapy or radiation therapy; prevention and treatment of nausea and vomiting in the postoperative period.

Pharmacological effect

Ondansetron is an antiemetic drug.

Ondansetron effectively prevents and eliminates nausea and vomiting that occurs during antitumor chemotherapy or radiation therapy, as well as in the postoperative period. The mechanism of action is due to the ability of ondansetron to selectively block serotonin 5-HT3 receptors.

It is believed that stimulation of the afferent fibers of the vagus nerve by serotonin released from the enterochromaffin cells of the gastrointestinal mucosa plays an important role in the occurrence of nausea and vomiting during antitumor therapy. By blocking 5-HT3 receptors, ondansetron prevents the gag reflex.

In addition, ondansetron inhibits the central parts of the gag reflex, blocking 5-HT3 receptors in the bottom of the fourth ventricle (area postrema).

Special instructions

It is not recommended to administer it in the same syringe with other drugs.

Injection forms are diluted only with recommended solutions. Compatible with infusion solutions of sodium and potassium chloride, dextrose, mannitol, Ringer.

Before introducing them, you should ensure that there are no large particles or color changes (if the container allows); the precipitate contained on the walls of the ampoule (does not affect activity or safety) is dissolved by vigorous shaking; ampoules are not autoclaved and are protected from light exposure.

Active ingredient

Ondansetron

Composition

1 ampoule contains:

Active substance:

ondansetron (as hydrochloride dihydrate) 2 mg.

Contraindications

I trimester of pregnancy, increased sensitivity to ondansetron.

Side Effects

From the gastrointestinal tract: constipation/diarrhea, dry mouth, hiccups, transient increase in AST and ALT levels.

From the nervous system and sensory organs: headache, dizziness, spontaneous movement disorders and convulsions, impaired visual acuity, extrapyramidal disorders (with parenteral use).

From the cardiovascular system and blood (hematopoiesis, hemostasis): fainting, chest pain, in some cases with ST segment depression, bradycardia, arrhythmia, arterial hypotension.

Allergic reactions: urticaria, bronchospasm, laryngospasm, angioedema, anaphylaxis.

Other: fever, sensation of heat, flushing, hypokalemia, hypercreatinemia, local reactions (pain, redness and burning at the injection site); burning in the anus and rectum (suppositories).

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

2 years

Manufacturer

PharmFirma Sotex, Russia